{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"22","value":"18"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"9","value":"8"},{"groupId":"OG002","lowerLimit":"7","upperLimit":"13","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"description":"The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG000","title":"Soft Tissue Sarcoma"},{"description":"Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \\[de-differentiated or mesenchymal\\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG001","title":"Bone Sarcoma"},{"description":"Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks","id":"OG002","title":"Expansion Cohort"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 5 yrs","title":"The Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}